


Glioblastoma*





MARKET*











CAGR 3-10%

Dynamic of

2023


283

deals announced

4

new biologics entering the pipeline

Distribution by type of biologics Gene-Modified Cell T







KEY EPIDEMIOLOGICAL DATA

2-3

cases

for 100 000 peoples

14,6

months

overall survival

14,5%

of all CNS tumors

